星球细胞在阿尔茨海默氏病期间对神经炎症的反应中升高调节互白素-15
Benjamin C Shaw1, Kaitlin E Kaiser1, Brandon C Smith1
1Department of Neurosciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA.
Journal of Alzheimer's disease : JAD
|November 5, 2025
概括
阿尔茨海默病 (AD) 涉及从粉样斑块附近的天体细胞中增加的互白素-15 (IL-15). 神经元表达IL-15的受体,表明在AD神经炎症中起作用.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 干白素-15 (IL-15) 涉及认知功能,在阿尔茨海默氏症 (AD) 脑脊液中升高.
- 在AD中IL-15和IL-15感应细胞的细胞起源仍然未确定.
研究的目的:
- 为了确定在AD中分泌IL-15的特定细胞类型.
- 为了研究IL-15生产和粉样β (Aβ) 病理学之间的空间关系.
主要方法:
- 人类死后脑组织的免疫光标记.
- RNA测序和体外细胞培养试验.
- 在5xFAD小鼠海马体样本上进行多重ELISA.
主要成果:
- 星球细胞 (GFAP+) 在AD大脑中的Aβ斑块附近显示IL-15的局部化增加.
- 星球细胞,而不是神经元,在对干扰素-γ和瘤亡因子-α的反应中对IL-15进行上调调节.
- 神经元表现出增加的IL2Rγ和IL2Rβ表达与更高的布拉克得分;IL-15在5xFAD小鼠海马中升高.
结论:
- 星球细胞是AD中IL-15的重要来源,特别是在Aβ沉积物的邻近.
- 神经元拥有响应IL-15的机制,这表明在AD病变发生过程中可能发挥作用.
- 5xFAD小鼠模型有效地模仿了AD的海马炎症环境,作为研究IL-15作用的宝贵工具.
相关概念视频
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801


